Highlights the broader potential of Orchards ex vivo HSC gene therapy platform approach in new and larger indications
Reinforces Pharmings commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure
Companies to host joint investor call at 8:00 a.m. EDT / 2:00 p.m. CEST
BOSTON, LONDON and LEIDEN, The Netherlands, July 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, and Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company, today announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.
OTL-105 is an investigational HSC gene therapy designed to increase C1 esterase inhibitor (C1-INH) in HAE patient serum to prevent hereditary angioedema attacks. OTL-105 inserts one or more functional copies of the SERPING1 gene into patients own HSCs ex vivo which are then transplanted back into the patient for potential durable C1-INH production. In preclinical studies, to date, OTL-105 demonstrated high levels of SERPING1 gene expression via lentiviral-mediated transduction in multiple cell lines and primary human CD34+ HSCs. Furthermore, the program achieved production of functional C1-INH protein, as measured by a clinically validated assay.
Under the terms of the collaboration, Pharming has been granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings, and commercialization of the investigational gene therapy, including associated costs. Orchard will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during pre-clinical and clinical development, which will be funded by Pharming. In addition, both companies will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.
Orchard will receive an upfront payment of $17.5 million comprising $10 million in cash and a $7.5 million equity investment from Pharming at a premium to Orchard's recent share price. Orchard is also eligible to receive up to $189.5 million in development, regulatory and sales milestones as well as mid-single to low double-digit royalty payments on future worldwide sales.
Given the combination of our expertise in HSC gene therapy with Pharmings long-standing legacy and experience, we have the potential to reinvent the treatment paradigm for HAE by providing people living with this life-threatening disorder a sustained therapy with a single administration, said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard Therapeutics. This collaboration demonstrates the promise of the HSC gene therapy platform and how it can be applied to new therapeutic areas with larger patient populations. We believe the HSC gene therapy pipeline we are building could continue to be a source of future partnerships in areas where the biology supports our approach.
Pharming has been committed to the HAE community for more than two decades, said Sijmen de Vries M.D., MBA, chief executive officer of Pharming. We have partnered with Orchard Therapeutics, a leader in the development of autologous HSC gene therapy, to develop a potentially curative treatment for HAE. Based on Pharmings experience in HAE, we believe that HSC gene therapy has the potential for the highest probability of success. This confidence is based on the durability of effect and safety observed in approved treatments from Orchards HSC gene therapy portfolio and positive clinical data in several other programs. This a significant first step in developing a potentially transformative one-time treatment for HAE.
Great progress has been made in HAE treatment over the last 15 years.However, HAE remains a severe, debilitating disease with an ongoing burden of angioedema attacks or chronic medication use, said Dr. MarcRiedl, professor of medicine and clinical director of the U.S. Hereditary Angioedema Association Center at the University of California, San Diego.This promising work toward treatment with the potential for durable long-term clinical benefit is encouraging and signifies an ongoing commitment to the HAE community.I look forward to these efforts to identify and carefully advance a potential cure for HAE.
The HAE market is expected to generate ~$2 billion in sales in 2021, currently growing at 8% per annum. This represents a significant commercial opportunity for Pharming Group and Orchard Therapeutics.
Webcast Link:https://webcast.openbriefing.com/pharming-jul21/
Access code:470719
About HAE Hereditary angioedema (HAE) is a rare genetic disorder. The condition is caused by a deficiency of the C1 esterase inhibitor protein, which is normally present in blood and helps control inflammation (swelling) and parts of the immune system. Deficient C1 inhibitor does not adequately perform its regulatory function and, as a result, a biochemical imbalance can occur and produce unwanted peptides that induce the capillaries to release fluids into surrounding tissue, thereby causing swelling or edema.
HAE is characterized by spontaneous and recurrent episodes of swelling (edema attacks) of the skin in different parts of the body, as well as in the airways and internal organs. Edema of the skin usually affects the extremities, the face, and the genitals. Patients suffering from this kind of edema often withdraw from their social lives because of the disfiguration, discomfort and pain these symptoms may cause. Almost all HAE patients suffer from bouts of severe abdominal pain, nausea, vomiting and diarrhea caused by swelling of the intestinal wall.
Edema of the throat, nose or tongue is particularly dangerous and potentially life-threatening as it can lead to obstruction of the airway passages. Although there is currently no known cure for HAE, it is possible to treat the symptoms associated with angioedema attacks. HAE affects about 1 in 10,000 to 1 in 50,000 people worldwide. Experts believe a lot of patients are still seeking the right diagnosis: although HAE is (in principle) easy to diagnose, it is frequently identified very late or not discovered at all. The reason HAE is often misdiagnosed is because the symptoms are similar to those of many other common conditions such as allergies or appendicitis. By the time it is diagnosed correctly, the patient has often been through a long ordeal.
About Pharming Group N.V.Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.
Our lead product, RUCONEST, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST in the United States, the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.
In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury, and severe pneumonia as a result of COVID-19 infections.
Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.
About Orchard TherapeuticsOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About Orchard TherapeuticsInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter andLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Orchard Therapeutics Forward-looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, and the possibility of future milestone or royalty payments. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates, will be insufficient to support regulatory submissions or marketing approval in the US or EU, as applicable, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchards ability to commercialize its product candidates, if approved, or Libmeldy in the EU; the risk that the market opportunity for Libmeldy, or any of Orchards product candidates, may be lower than estimated; the risk that certain milestones may never be achieved or royalty payments may never be earned and paid; and the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.
Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2021, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Pharming Group N.V. Forward-looking Statements This press release contains forward-looking statements, including with respect to timing and progress of Pharmings preclinical studies and clinical trials of its product candidates, Pharmings clinical and commercial prospects, Pharmings ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharmings expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharmings clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharmings 2020 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharmings actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.
Inside InformationThis press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Orchard Therapeutics Contacts
InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com
MediaBenjamin NavonDirector, Corporate Communications+1 857-248-9454Benjamin.Navon@orchard-tx.com
Pharming Group N.V. Contacts
CompanyPharming Group, Leiden, The NetherlandsSijmen de Vries, CEO+31 71 524 7400
InvestorsSusanne EmbletonInvestor Relations Manager+31 71 524 7400investor@pharming.com
Media FTI Consulting, London, UKVictoria Foster Mitchell/Alex Shaw +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The NetherlandsLeon Melens+31 6 53 81 64 27pharming@lifespring.nl
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as... - January 6th, 2020